ClinicalTrials.Veeva

Menu

Treatment of Surgical Scars Following Breast Augmentation, Abdominoplasty or Face Lift

Venus Concept logo

Venus Concept

Status

Completed

Conditions

Face Lift
Breast Augmentation
Surgical Scar
Abdominoplasty

Treatments

Device: Fractional Radiofrequency (FRF)

Study type

Interventional

Funder types

Industry

Identifiers

Details and patient eligibility

About

Evaluator-blinded study of the safety and performance of fractional radiofrequency (FRF) for the treatment of surgical scars following breast augmentation, abdominoplasty or facelift. The study will enroll up to 50 female subjects requesting treatment of surgical scars following breast augmentation or abdominoplasty and up to 25 male and female subjects requesting treatment of surgical scars following facelift surgery. Subjects will receive a total of 3 treatments of their surgical scars at 1-month intervals. Subjects will be followed up at 10 months after their last treatment (12 months after the first treatment).

Enrollment

54 patients

Sex

All

Ages

20 to 75 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  1. Healthy, female, subjects 20-60 years of age who are seeking treatment for their breast augmentation or abdominoplasty surgical scars or male and female patients 40-75 years of age who are seeking treatment for their face lift surgical scars.
  2. A minimum of four weeks since surgery.
  3. Able to read, understand and voluntarily provide written Informed Consent.
  4. Able and willing to comply with the treatment/follow-up schedule and requirements.
  5. Willing to avoid direct sunlight for the duration of the study.
  6. Women of child-bearing age are required to be using a reliable method of birth control at least 3 months prior to study enrollment and for the duration of the study, and have a negative Urine Pregnancy test at baseline.

Exclusion criteria

    1. Fitzpatrick skin types 5-6. 2. Implantable defibrillators, cardiac pacemakers, and other metal implants 3. Subjects with any implantable metal device in the treatment area 4. Pacemaker or internal defibrillator, or any other active electrical implant anywhere in the body (e.g. cochlear implant).

    2. Permanent implant in the treated area, such as metal plates and screws, or an injected chemical substance.

    3. Current or history of any kind of cancer, or pre-malignant moles. 7. Severe concurrent conditions, such as cardiac disorders. 8. Pregnancy or intending to become pregnant during the study and nursing. 9. Impaired immune system due to immunosuppressive diseases, such as AIDS and HIV, or use of immunosuppressive medications.

    4. History of diseases stimulated by heat, such as recurrent herpes simplex in the treatment area; may be enrolled only following a prophylactic regime.

    5. Poorly controlled endocrine disorders, such as diabetes. 12. Any active condition in the treatment area, such as sores, psoriasis, eczema, and rash.

    6. History of skin disorders, such as keloids, abnormal wound healing, as well as very dry and fragile skin.

    7. History of bleeding coagulopathies, or use of anticoagulants. 15. Use of isotretinoin (Accutane®) within six months prior to treatment. 16. Treating over tattoo or permanent makeup. 17. Excessively tanned skin from sun, tanning beds or tanning creams within the last two weeks.

    8. As per the practitioner's discretion, refrain from treating any condition which might make it unsafe for the patient.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

54 participants in 1 patient group

Fractional radiofrequency (FRF)
Experimental group
Description:
Subjects received 3 FRF treatments (monthly) over their scar following breast augmentation, abdominoplasty or face lift surgery.
Treatment:
Device: Fractional Radiofrequency (FRF)

Trial documents
1

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems